This Italian multicenter retrospective study compared the drug survival and efficacy of different anti-TNF agents in psoriasis (PsO) and psoriatic arthritis (PsA) patients. A database of PsO/PsA patients treated with adalimumab, etanercept, and infliximab from May 2013 to May 2014 was analyzed. PASI 75, 90, and 100 was calculated at each time point to evaluate efficacy. Drug survival rate and probability of maintaining PASI response were evaluated. The impact of dependent variables on probability of PASI 75 loss was evaluated by logistic regression. 1,235 patients were included, 577 with PsO and 658 with PsA. Highest survival rates were observed with adalimumab followed by etanercept and infliximab in PsO and PsA patients. The probability of maintaining PASI response was significantly higher for adalimumab followed by infliximab. For PsO patients, the odds of losing PASI 75 was higher in etanercept-treated patients (OR: 8.1; 95% CI: 4.2-15.6, p < .001) or infliximab (OR: 6.6; 95% CI: 2.6-16.3, p < .001) vs. adalimumab. Likewise, for PsA patients the odds of losing PASI 75 was higher in etanercept-treated patients (OR: 2.3; 95% CI:
| I NTR OD U CTI ON
Psoriasis (PsO) and psoriatic arthritis (PsA) are chronic and invalidating diseases affecting 1-3% and 0.16-0.25% of the world population, respectively (Haddad & Chandran, 2012) . Psoriasis is an inflammatory skin disease requiring lifelong care; plaque psoriasis being the most common form (90%), characterized by painful and itchy erythematous plaques, usually covered with flaking silver scales and localized on scalp, elbows, and knees or generalized disease across wider areas of the body (Canadian Psoriasis Guidelines Committee, 2009; Menter, Gottlieb, and Feldman, 2008) . PsA is a chronic inflammatory seronegative spondyloarthropathy associated with PsO (Gottlieb, Korman, & Gordon, 2008; Scottish Intercollegiate Guidelines Network (SIGN), 2010) , with an estimated prevalence in PsO patients of 25-40% (Gottlieb & Dann, 2009; Laws, Barton, and Warren, 2010) . The visible plaques of PsO have a strong impact on physical and mental functions similar to that of other severe chronic diseases, (Rapp, Feldman, Exum, Fleischer, & Reboussin, 1999) with high levels of stress, poor self-esteem, increased rates of mood disorders and detrimental effects on social functioning, interpersonal relationships and productivity (Eghlileb, Davies, & Finlay, 2007) . PsA patients may develop severe skeletal changes in addition to cutaneous signs, with a negative impact on function and quality of life (Gossec & Smolen, 2015) . A delay in the diagnosis of PsA that is associated with adverse long term outcome, such as joint damages and associated disabilities; the early detection of PsA can prevent these significant complications (Gossec & Smolen, 2015; McHugh, 2015) .
Treatment strategies of severe or refractory/recalcitrant PsO/PsA recommended by International and National Guidelines are based on disease-modifying drugs (DMARDs), such as methotrexate and cyclosporine. In cases of inadequate response, contraindication or intolerance to at least one DMARD, a therapy with a biologic drug such as tumor necrosis factor (TNF) inhibitors (adalimumab, infliximab, etanercept, golimumab) or anti-interleukin therapies (ustekinumab) should be considered (Canadian Psoriasis Guidelines Committee, 2009; Gossec & Smolen, 2015; Gossec, Smolen, and Gaujoux-Viala, 2012; Il Trattamento della Psoriasi Nell'adulto, 2013; Menter et al., 2008; NICE Clinical Guideline Centre, 2012; Salvarani, Pipitone, and Marchesoni, 2011;  Scottish Intercollegiate Guidelines Network (SIGN), 2010). Furthermore, in February 2016, adalimumab was approved by the European Medicines Agency for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy and not only after previous inadequate response/intolerance to systemic DMARDs (European Medicines Agency, 2016). TNF, a pleiotropic cytokine which regulates several inflammatory reactions and immune functions through the control of cellular processes, plays a central role in the pathogenesis of PsO and PsA. The over-expression of TNF is able to promote pro-inflammatory conditions and is involved in several pathogenetic mechanisms such as the accumulation of leukocytes in the inflamed skin, induction of dermal vascular changes and itching, and inflammation and joint-bone damage . TNF inhibitors represent effective therapeutic options for the treatment of PsO and PsA, significantly improving signs and symptoms and reducing the disease activity. These drugs represent an outstanding innovation in the treatment of inflammatory immunomediated diseases and an important option for modifying the natural course and the unfavorable progression of these diseases (Blandizzi, 2013; Furst, Keystone, and Braun, 2012; Raval, Lofland, Waters, & Piech, 2011) . The anti-TNF agents adalimumab, etanercept and infliximab are indicated both in PsA and PsO (Enbrel® (Etanercept), 2015; Humira® (Adalimumab), 2015; Remicade® (Infliximab), 2015; Simponi® (Golimumab), 2015; Stelara®, (ustekinumab), 2015) .
National registries provide clinical data from the real-world setting, with the main aim to monitor long-term safety of specific treatments in the clinical setting, but they also contain other important information difficult to collect in clinical trials, such as drug usage, real-life longterm effectiveness, the impact on quality of life (QoL), and related economic issues .
The aim of this retrospective study was to collect epidemiological and management information on PsO/PsA patients treated with TNF inhibitors in real life. Real life data reflect the daily clinical practice, differently from randomized clinical trials, where stricter inclusion/exclusion criteria are adopted for selecting study populations. (Finlay, 2005) and all PsA patients met the CASPAR (ClASsification criteria for Psoriatic ARthritis) criteria for the classification of PsA (Taylor, Gladman, & Helliwell, 2006) . The database was designed to record demographic and anamnestic data, concomitant diseases, current and previous biologic treatments, Psoriasis Area Severity Index (PASI) score during the observational period (visits: 0, 3 months, 
| Outcome measures
To evaluate the efficacy of each anti-TNF agent, the response rate of a 75%, 90%, and 100% improvement in the PASI score (respectively PASI 75, PASI 90, and PASI 100) was calculated at each time point. The survival rate and probability of maintaining PASI 75, 90, and 100 responses were evaluated for each treatment over the entire observation period.
| Statistical analysis
Data are presented as mean 6 standard deviation for continuous variables, and absolute and relative frequency distribution for categorical data. Comparisons between groups were performed by the Chi- Table S1 . There were a higher proportion of male patients in both the PsO (71.3%) and PsA (57.1%) groups. PsA patients were slightly older (55 vs. 50 years) and PASI score was higher in PsO patients (range 11-18 vs. 4-14) . Clinical characteristics prior to initial anti-TNF treatment were well matched across groups (Supporting Information Table S1 ).
| Probability of maintaining treatment
In PsO patients the probability of maintaining treatment over the 8-year follow-up period was highest in those treated with adalimumab compared to those treated with etanercept (p 5 .061) or infliximab (p < .001) (Figure 1a) . At 6 years, the probability of maintaining adalimumab treatment (0.62; 95%CI: 0.52-0.7) was approximately 10% higher than etanercept (0.49; 95% CI: 0.42-0.56) and about 30% higher than infliximab (0.33; 95% CI: 0.21-0.44).
In PsA patients, although patients treated with etanercept had a similar probability of maintaining treatment compared to adalimumab at 2 years (0.76; 95% CI: 0.72-0.80 vs. 0.74; 95% CI: 0.68-0.79, respectively), adalimumab-treated patients had higher probability of maintaining treatment for the remainder of the follow-up period ( Figure 1b) . As expected, no statistically significant difference was noted between the probability of maintaining treatment for these 2 groups (p 5 .91), over the entire follow-up period however, infliximab treated patients revealed significantly lower probability of maintaining treatment compared to adalimumab (p < .001) and etanercept (p < .001). where a statistically significant difference was observed between adalimumab and etanercept (p 5 .050) or infliximab (p < .01) (Figure 2f ).
| PASI clinical response rate
The clinical response was evaluated as the rate of patients attaining PASI 75, 90, or 100 over the 7 year follow up period. Figure 3 shows the rate of PsO and PsA patients with PASI 75, 90, and 100 response stratified by anti-TNF treatment. The proportion of PsO patients with PASI 75 over the follow up period was higher for adalimumab vs.
etanercept and infliximab (Figure 3a) . Similarly, a higher proportion of patients attained PASI 90 treated with adalimumab compared to etanercept or infliximab as well as those patients with PASI 100 (Figure 3b,c) . In contrast, in PsA patients, no differences in terms of PASI 75 response rate were observed among the three treatments (Figure 3d ). PASI 90 and PASI 100 responses were markedly higher in patients treated with adalimumab compared with patients treated with etanercept (Figure 3e,f) . A higher PASI 100 response rate was observed for adalimumab vs. infliximab (Figure 3f ).
| Impact of predictor variables on PASI 75 loss
Logistic regression analysis was used to evaluate the impact of independent variables on the probability of PASI 75 loss in the PsO PsO patients, univariate analysis revealed that etanercept and infliximab compared to adalimumab treatment increased the odds of PASI loss by 8.9-(95% CI: 14.7-16.9) and 6.6-fold (95% CI: 2.78-15.7), respectively. The presence of 1 or > 1 previous therapies were associated with a protective effect against PASI 75 loss as was baseline PASI, where every 1 unit increase in baseline PASI was associated with a 5% reduction in odds of PASI 75 loss. Multivariate logistic analysis was performed excluding variables that had a p value .2 following univariate analysis. In addition to baseline PASI having a protective effect on PASI 75 loss, etanercept (Odds ratio: 8.1, 95% CI: 4.2-15.6, p < .001) and infliximab (Odds ratio: 6.6, 95% CI: 2.6-16.3, p < .001) compared to adalimumab treatment still emerged as strong predictors of PASI 75 loss. The effect of biologic therapy had less of an impact on PASI 75 loss in PsA patients (Supporting Information Table S2 , lower panel). Univariate analysis showed that etanercept and infliximab compared to adalimumab treatment increased the odds of PASI 75 loss by 2.33-(95% CI: 1.4-3.8, p 5 .001) and 2.32-fold (95% CI: 1.14-4.1, p 5 .01), respectively.
Baseline PASI was not associated with PASI 75 loss. Etanercept (Odds ratio: 2.29, 95% CI: 1.4-3.77, p 5 .001) and infliximab (Odds ratio: 2.19, 95% CI: 1.14-4.14, p 5 .018) compared to adalimumab treatment still emerged as significant predictors of PASI 75 loss following multivariate logistic analysis.
| D I SCUSSION
The main outcome measure examined in this retrospective study, carried out in a routine clinical setting using the data of a clinical database of PsO/PsA patients treated with biological drugs in 6 Italian centers, was the drug survival, which reflects a drug's effectiveness, safety and tolerability. Drug survival is based on several factors such as dosage, effectiveness, improvement of the quality of life, safety and compliance and could be considered an overall marker for treatment success.
Gisondi et al. recently demonstrated that the retention rate (the number of patients who maintain the same therapy during a given period of treatment) of TNF-alpha inhibitors was significantly higher compared with conventional systemic treatment (DMARDs), due to a better tolerability (Gisondi, Tessari, Di Mercurio, Del Giglio, & Girolomoni, 2013) . In fact, the number of patients who discontinued TNFalpha inhibitors was lower than that of DMARDs. No differences were noted among TNF-alpha inhibitors (Gisondi, Tessari, & Di Mercurio, 2013 ). An Italian experience (BEETLE study) evaluated 1,219 patients Our results show that in PsO patients, adalimumab has the highest survival rate, statistically superior to that of etanercept and infliximab.
These results are partially in contrast with other recent epidemiological surveys (Esposito, Gisondi, & Cassano, 2013; Gniadecki, Kragballe, Dam, & Skov, 2011; Gniadecki, Bang, and Bryld, 2015) . Gniadecki et al. evaluated the data of the Danish prospective nationwide database DERMBIO (registry for PsO patients showing that in the group of anti-TNF-a-naive patients, the longest drug survival was observed for infliximab, followed by adalimumab and etanercept (Gniadecki, Kragballe, & Dam, 2011) . A recently published update of this study included 1,867 treatment series over a period of 10 years. In this study, drug survival was significantly longer for ustekinumab than for the anti-TNF-alpha inhibitors (p < .001). In particular, adalimumab and infliximab had comparable median survival rates and etanercept had the shortest survival time (Gniadecki et al., 2015) .
Our data confirmed previously reported data from several registrybased studies (Brunasso, Puntoni, & Massone, 2012; Iskandar, et al. 2015May18; Menting, Sitaram, & Bonnerjee-van der Stok, 2014; van den Reek et al., 2014; Warren et al., 2015) . In a retrospective cohort study evaluating tolerability and safety of biological drugs (adalimumab, efalizumab, etanercept, and infliximab) in 108 PsO patients infliximab was significantly associated with a shorter adherence to therapy compared with adalimumab, etanercept, and efalizumab (Brunasso et al., 2012) . The British Association of Dermatologists Biologic Interventions Register (BADBIR) is a prospective, observational database designed to evaluate the long-term safety of biologic and conventional systemic treatments for adults with moderate-to-severe PsO in the U.K. and Republic of Ireland. 5,065 (60%) out of 8,399 patients included in BAD-BIR received a biologic drug: 52.8% adalimumab, 24.6% etanercept, 18.7% ustekinumab, and 3.9% infliximab (Iskandar et al., 2015) . Warren et al. calculated the survival rates of the first course of biologics for 3523 biologic-naïve patients with chronic plaque PsO enrolled in BADBIR database. The overall survival rate in the first year was 77% and 53% in the third year. In particular, patients treated with etanercept or infliximab were more likely to discontinue therapy compared with adalimumab or ustekinumab (Warren et al., 2015) . (Menting et al., 2014) .
According to our data, in PsA patients the probability of remaining in treatment was higher for adalimumab, significantly lower for etanercept, followed by infliximab. Our findings contrast with those in other reports. The retrospective study by Fabbroni et al. evaluated treatment persistence rates and causes of discontinuation in 268 PsA and ankylosing spondylitis patients treated with biological drugs in clinical practice (Fabbroni, Cantarini, & Caso, 2014) . The comparison among the 3 anti-TNF drugs showed a difference in terms of drug survival: a withdrawal was required in 28.9% of patients treated with adalimumab, 22.8% of patients treated with etanercept and in 38.2% of those treated with infliximab; the difference between etanercept and infliximab was statistically significant (p 5 .0058) (Fabbroni et al., 2014 ). An epidemiological observational cohort study from The Danish biologics registry DANBIO evaluated the patients' clinical response and drug survival to anti-TNF-alpha inhibitors of 764 PsA patients (Glintborg, Østergaard, & Dreyer, 2011) . The results showed that the median drug survival was 2.9 years, and 1-year and 2-year drug survival rates were 70% and 57%, respectively. In particular, no differences were observed in terms of retention rates, which were similar among patients receiving infliximab, adalimumab and etanercept (Glintborg et al., 2011) .
Considering the efficacy outcome based on PASI response and the survival rate, in our experience adalimumab was the most effective treatment both in PsO and in PsA patients. These efficacy results are similar to or even higher than those reported in clinical trials (Armesto, Coto-Segura, Mayorga, Illaro, & Santo-Juanes, 2015; Esposito, Giunta, and Mazzotta, 2012; Gordon et al., 2012; Lopez-Ferrer, Vilarrasa, Gich, & Puig, 2013; Menter et al., 2008; Papp, Ho, and Teixeira, 2012; Papp, et al. 2009September-October) . Some recent meta-analyses and direct/ indirect comparisons evaluated the effectiveness of available biological drugs in PsO and PsA patients. Overall, the results showed that there were no significant differences between the drugs in relation to the efficacy outcomes, except for a superiority of ustekinumab, adalimumab and infliximab versus etanercept in terms of PASI response in PsO patients (Galvan-Banqueri, Marín Gil, Santos Ramos, & Bautista Paloma, 2013; Puig, Lopez, Vilarrasa, & García, 2014; Reich, Burden, Eaton, & Hawkins, 2012; Schmitt, Rosumeck, and Thomaschewski, 2014 
| Study strengths and limitations
This study is of particular value as it provides longitudinal data (collected retrospectively) from 1,235 patients, (577 in the PsO group and 658 in the PsA group) from 6 centers with follow-up times ranging from 6 months to 8 years. To date, few studies are available that report data on this Italian population. However, there are some potential limitations that need to be addressed. Weaknesses of observational registries such as the reliability of results and incompleteness of data have previously been highlighted von Elm, Altman, and Egger, 2007) . Furthermore, the lack of randomization may also introduce selection bias, and the presence of unmeasured confounders cannot always be ruled out.
However, we did not observe any marked changes in clinical characteristics among treatment groups attributed to loss during follow-up.
This potential limitation was also addressed by including potential confounding variables in logistic regression models. It is recognized that efficacy and retention in therapy for biologics is correlated with line of treatment. Although the proportion of naive patients was not markedly different in the PsO (50-65%) and PsA groups (30-55%), our analysis did not specifically examine efficacy by line of treatment, which was not feasible due to the low sample sizes for this subanalysis. Last, our analysis was limited to the comparison of adalimumab, etanercept, and infliximab for the treatment of PsO and PsA patients. Few patients were treated with golimumab (N 5 47) to permit further analysis and certolizumab was not available in Italy at the time this study was undertaken.
| CON CLU S I ON S
Real-life data, typically collected by national registers and noninterventional studies, represent an important source of information on long-term treatment, efficacy and safety in day-to-day conditions of clinical practice and among heterogeneous groups of patients, such as elderly subjects or patients with comorbidities or co-medications, usually excluded from randomized controlled trials.
